Aprotinin counteracts heparin-induced inhibition of platelet contractile force

Thrombosis Research

Volumn 108, Issue 2-3, 2002, Pages 161-168

  Carr Jr , Marcus E ^a,b   Carr, Sheryl L ^a   Roa, Veronica ^a,b   McCardell, Kathleen A ^a,b   Greilich, Philip E ^c,d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Childrens Medical Center of Dallas   (United States)

Author keywords

Aprotinin; Cardiopulmonary bypass; Clot retraction; Heparin; Platelet contractile force; Platelet dysfunction

Indexed keywords

APROTININ; ATROXIN; BATROXOBIN; CALCIUM CHLORIDE; HEPARIN;

ARTICLE; BLEEDING; CONTROLLED STUDY; HUMAN; IONIC STRENGTH; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE RICH PLASMA;

EID: 0036878199     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00403-6     Document Type: Article

References (48)

1. Woodman R.C., Harker L.A. Bleeding complications associated with cardiopulmonary bypass. Blood. 76:1990;1680-1697.
2. Harker L.A., Malpass T.W., Branson H.E., Hessel E.A. II, Slichter S.J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective α-granule release. Blood. 56:1980;824-834.
3. Kestin A.S., Valeri C.R., Khuri S.F., Loscalzo J., Ellis P.A., MacGregor H.et al. The platelet defect of cardiopulmonary bypass. Blood. 82:1993;107-117.
4. van Oeveren W., Harder M.P., Roozendaal K.J., Eijsman L., Wildevuur C.R. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 99:1990;788-797.
5. van Oeveren W., Jansen N.J., Bidstrup B.P., Royston D., Westaby S., Neuhof H.et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann. Thorac. Surg. 44:1987;640-645.
6. John L.C., Rees G.M., Kovacs I.B. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann. Thorac. Surg. 55:1993;1175-1179.
7. 14C]5-hydroxytryptamine release. Br. J. Haematol. 36:1977;427-436.
8. Sobel M., McNeill P.M., Carlson P.L., Kermode J.C., Adelman B., Conroy R.et al. Heparin inhibition of von Willebrand Factor-dependent platelet function in vitro and in vivo. J. Clin. Invest. 87:1991;1787-1793.
9. Greilich P.E., Carr M.E., Carr S.L., Chang A.S. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth. Analg. 80:1995;459-465.
10. Dietrich W., Spannagl M., Jochum M., Wendt P., Schramm W., Barankay A.et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 73:1990;1119-1126.
11. Wachtfogel Y.T., Kucich U., Hack C.E., Gluszko P., Niewiarowski S., Colman R.W.et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J. Thorac. Cardiovasc. Surg. 106:1993;1-10.
12. Lavee J., Savion N., Smolinsky A., Goor D.A., Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann. Thorac. Surg. 53:1992;477-481.
13. Mohr R., Goor D.A., Lusky A., Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscopic study. Circulation. 86:1992;II405-II409.
14. Carr M.E., Zekert S.L. Measurement of platelet-mediated force development during plasma clot formation. Am. J. Med. Sci. 302:1991;13-18.
15. Carr M.E., Carr S.L. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. Blood Coagul. Fibrinolysis. 6:1995;79-86.
16. Carr M.E., Carr S.L., Hantgan R.R., Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet mediated force development and reduces gel elastic modulus. Thromb. Haemost. 73:1995;499-505.
17. Greilich P.E., Alving B.M., O'Neill K.L., Chang A.S., Reid T.J. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth. Analg. 84:1997;31-38.
18. Greilich P.E., Alving B.M., Longnecker D., Carr M.E., Whitten C.W., Chang A.S.et al. Near-site monitoring of the antiplatelet drug ABCIXIMAB using the Hemodyne® analyzer and modified Thromboelastograph® J. Cardiothorac. Vasc. Anesth. 13:1999;58-64.
19. Carr ME. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem. Biophys. [in press].
20. Carr M.E., Zekert S.L. Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: report of a case. Blood Coagul. Fibrinolysis. 2:1991;303-308.
21. Carr M.E., Hackney M.H., Hines S.J., Heddinger S.P., Carr S.L., Martin E.J. Enhanced platelet force development despite drug induced inhibition of platelet aggregation in patients with thromboangiitis obliterans. Vasc. Endovasc. Surg. 36:2002;473-480.
22. Carr M.E., Carr S.L., Tildon T., Fisher L.M., Martin E.J. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. J. Thromb. Haemost. [in press].
23. Carr M.E., Carr S.L. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb. Res. 75:1994;617-630.
24. Carr M.E., Carr S.L., Greilich P.E. Heparin ablates force development during platelet mediated clot retraction. Thromb. Haemost. 75:1996;674-678.
25. Carr M.E., Martin E.J., Carr S.L. Delayed, reduced and inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul. Fibrinolysis. 13:2002;193-197.
26. Carr M.E., Zekert S.L. Effect of non-heparin thrombin antagonists on platelet force development during dot retraction. Cell Biochem. Biophys. 69:1993;1241.
27. Greilich P.E., Carr M.E., Zekert S.L., Dent R.M. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am. J. Med. Sci. 307:1994;15-20.
28. Carr M.E. Diabetes mellitus: a hypercoagulable state. J. Diabetes Complications. 15:2001;44-54.
29. Carr M.E., Krishnaswami A., Martin E.J. Elevated platelet contractile force (PCF) and clot elastic modulus (CEM) in diabetic patients: a potential marker of increased thrombotic risk. Diabet. Med. 19:2002;862-866.
30. Krishnaswami A., Carr M.E., Jessie R.L., Kontos M., Minisi A.J., Ornato J.P.et al. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb Haemost. 88:2002;739-744.
31. Clauss A. A rapid physiological coagulation method for determination of fibrinogen. Acta Haematol. 17:1957;237-246.
32. Carr M.E., Zekert S.L. Abnormal clot retraction, altered fibrin structure and normal platelet function in multiple myeloma. Am. J. Physiol. 266:1994;H1195-H1201.
33. Carr M.E., Gabriel D.A. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J. Lab. Clin. Med. 96:1980;985-993.
34. Carr M.E., Alving B.M. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul. Fibrinolysis. 6:1995;567-573.
35. Bidstrup B.P. Aprotinin as an adjuvant to blood conservation in open-heart surgery. Hemostasis in cardiac surgery. In: Safuh Attar, editor. Armonk, NY: Futura Publishing; p. 189-202.
36. Horne M.K., Chao S.C. Heparin binding to resting and activated platelets. Blood. 74:1989;238-243.
37. Carr M.E., Dent R.M. Protamine sulfate alters fibrin assembly and structure resulting in enhanced fibrinolysis. Clin. Res. 40:1992;420A.
38. John L.C.H., Rees G.M., Kovacs I.B. Inhibition of platelet function by heparin, an etiologic factor in postbypass hemorrhage. J. Thorac. Cardiovasc. Surg. 105:1993;816-822.
39. Santamaria A., Mateo J., Muniz-Diaz E., Oliver A., Murillo J., Litvan H.et al. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Haematologica. 85:2000;381-385.
40. Basora M., Gomar C., Escolar G., Pacheco M., Fita G., Rodriguez E.et al. Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin. J. Cardiothorac. Vasc. Anesth. 13:1999;382-387.
41. Shigeta O., Kojima H., Jikuya T., Terada Y., Atsumi N., Sakakibara Y.et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 96:1997;569-574.
42. Speekenbrink R.G., Wildevuur C.R., Sturk A., Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J. Thorac. Cardiovasc. Surg. 112:1996;523-530.
43. Kozek-Langenecker S.A., Mohammad S.F., Masaki T., Green W., Kamerath C., Cheung A.K. The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Anesth. Analg. 90:2000;12-16.
44. Wahba A., Black G., Koksch M., Rothe G., Preuner J., Schmitz G.et al. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb. Haemost. 75:1996;844-848.
45. Primack C., Walenga J.M., Koza M.J., Shankey T.V., Pifarre R. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann. Thorac. Surg. 61:1996;1188-1193.
46. Landis R.C., Asimakopoulos G., Poullis M., Haskard D.O., Taylor K.M. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann. Thorac. Surg. 72:2001;2169-2175.
47. Landis R.C., Haskard D.O., Taylor K.M. New antiinflammatory and platelet-preserving effects of aprotinin. Ann. Thorac. Surg. 72:2001;S1808-S1813.
48. Ferraris V.A., Ferraris S.P., Reich H., Rodriguez E., Huang M., Gupta A.et al. Thrombin receptor-related hemostatic defect after cardiopulmonary bypass. Semin. Thromb. Hemost. 22(4):1996;351-356.